NCT05709106 is a clinical trial of Rimegepant 75 MG in Migraine, sponsored by Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine.

Who is sponsoring NCT05709106?

NCT05709106 is sponsored by Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine.

What drugs are being tested in NCT05709106?

Interventions in NCT05709106: Rimegepant 75 MG.

Is NCT05709106 still recruiting?

NCT05709106 is currently completed. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT05709106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Completed Last updated 5 February 2026

What this trial tests

trial testing Rimegepant 75 MG in Migraine in 173 participants. Completed in 9 April 2025.

Timeline

11 January 2023

Primary endpoint
6 October 2024

9 April 2025

Quick facts

Lead sponsor	Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
Status	Completed
Study type	OBSERVATIONAL
Enrollment	173
Start date	11 January 2023
Primary completion	6 October 2024
Estimated completion	9 April 2025
Sites	1 location across China

Drugs / interventions tested

Rimegepant 75 MG (rimegepant-75-mg) — full drug profile →

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world. The main questions it aims to answer are: * \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine * \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine. 1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack. 2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine 3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications.
Özge A, Baykan B, Bıçakçı Ş, Ertaş M, et al · · 2024 · cited 11× · PMID 38938785 · DOI 10.3389/fneur.2024.1402569
First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.
Yang Z, Wang X, Niu M, Wei Q, et al · · 2024 · cited 4× · PMID 39333875 · DOI 10.1186/s10194-024-01873-5

Verify or expand the search:

Other trials of Rimegepant 75 MG

Trials testing the same drug.

NCT05399459 — Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) · Phase 3 · completed
NCT05211154 — Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine · Phase 4 · terminated

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05709106 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05709106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing